DESCRIPTION OF SOME CLINICAL AND SUBCLINICAL FEATURES OF PATIENTS WITH LATE-STAGE GASTRIC CANCER AT VIETNAM NATIONAL CANCER HOSPITAL

Anh Tú Đỗ , Mai Phương Trần

Main Article Content

Abstract

Objective: Description of some clinical and subclinical features of patients with late-stage gastric cancer at Vietnam National Cancer Hospital. Patients and methods: Cross-sectional descriptive study on 52 patients with the diagnosis of late-stage gastric cancer, no longer amenable to radical surgery, at Vietnam National Cancer Hospital from June 2016 to March 2020.  Results: The overall average age of patients is 63.8 years old, most patients are over 50 years old, the oldest is 75, and the youngest is 42 years old. The male/female ratio is 1,9/1. 17,3% of patients have stomach disease, and 7,7% of patients have a relative with cancer. Most patients have good physical condition PS 0-1 (84,6%). Abdominal pain is the most common symptom, accounting for 76.9% of cases, with bloating, indigestion, poor appetite, and weight loss accounting for 55.8%, 53.9%, and 51.9%. The poorly differentiated type accounts for the highest proportion (53,8%). 55,8% of patients received symptomatic surgery. 69,2% of patients had one metastatic site. The liver and peritoneum are the most common metastatic sites, 34,6%, and 30,8%, respectively. Conclusion: The average age of the patients is 63,8 years old, most patients are in good health, abdominal pain is the most common symptom, accounting for 76.9% of cases, and poorly differentiated type accounts for the highest proportion (53,8%). The liver and peritoneum are the most common metastatic sites at 34,6% and 30,8%, respectively.

Article Details

References

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung - 2021 - CA: A Cancer Journal for Clinicians
2. Yang T, Shen X, Tang X, et al. Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer. Tumori. 2011;97(4): 466-472. doi:10. 1177/030089161109700409
3. Nguyễn Khánh Toàn. Đánh giá kết quả của phác đồ XELOX trong điều trị ung thư dạ dày giai đoạn muộn tại bệnh viện K. Đại học Y Hà Nội. 2013. p 38
4. Tô Như Hạnh (2012). Đánh giá kết quả hóa trị liệu phác đồ EOX cho ung thư dạ dày giai đoạn muộn không còn khả năng phẫu thuật triệt căn. Đại học Y Hà Nội.
5. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J. 2014;55(12): 621-628. doi:10.11622/smedj. 2014174
6. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(4):623-629. doi:10.1007/s00280-007-0515-7
7. Yoshida M, Ohtsu A, Boku N, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol. 2004; 34(11):654-659. doi:10.1093/jjco/hyh120
8. Nguyễn Văn Hiếu, Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị phẫu thuật ung thư dạ dày sớm tại bệnh viện K từ 2000-2006. Tạp chí Ung thư học Việt Nam, 2008. Số 1: p. 176-181.
9. Wang CS, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF. Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J. 2002;25(12):792-802.